Investigators conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of brolucizumab ...

In response to a report of foreign material found in a sealed vial, Alcon Laboratories has initiated a voluntary recall of ...

The NYU Grossman School of Medicine launches a Journal Club series with Ophthalmology Times, featuring expert faculty ...

As 2024 comes to a close, we here at Ophthalmology Times and the greater Eye Care Network would like to thank you–the reader.

Alon Kahana, MD, PhD, discusses the role of interleukin-6 in thyroid eye disease and the potential of tourmaline Bio's IL-6 ...

Deepinder Dhaliwal, MD, LAc, discusses longterm outcomes of Descemet Stripping Only (DSO) for Fuchs dystrophy at NYU's ...

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect ...

Deepinder Dhaliwal, MD, LAc, explores advancements in managing Fuchs endothelial corneal dystrophy, highlighting Descemet ...

Glaukos submitted an NDA for Epioxa, a novel corneal cross-linking therapy for keratoconus, to the US FDA. Epioxa's Phase 3 trials demonstrated efficacy, safety, and tolerability, achieving primary ...

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for. This series features experts in ophthalmology sharing their ...

Investigators conducted a retrospective clinical audit to determine why patients do not adhere to the guidelines among about 9,000 patients in a practice. A research team from Great Britain identified ...

Faricimab shows superior durability and efficacy in treating neovascular AMD, DME, and CRVO, allowing for extended treatment intervals and reduced burden. In DME cases, faricimab outperformed ...